We work in an interdisciplinary community mental health service for persons with developmental disabilities (DDs) across the lifespan, and we therefore read with particular interest the article by Friedlander and others (1) on the use of atypical antipsychotics to treat adolescents and young adults with DDs.
In our clinical practice, we have also observed that some persons with DD at times experience a "dramatic and longlasting response to low-dose atypical neuroleptics" but that "this population, however, seems particularly sensitive to neuroleptic-induced movement disorders (NIMDs), hence caution and close monitoring are required" (1) . What we feel deserves greater emphasis for practitioners less familiar with this etiologically and symptomatically diverse population with different types and degrees of DD is that the diagnostic complexities involved are substantial. Even establishing a diagnosis of schizophrenia or autism-pervasive developmental disorder (PDD) can be challenging; differentiating symptoms of psychosis from symptoms of anxiety in persons with autism-PDD can be still more problematic. Friedlander and others did not comment on these challenges in their paper, nor did they attempt to tease apart whether outcome was due to the atypical antipsychotic medication per se or whether and to what extent associated interventions with other medications or nonpharmacologic therapies may have contributed (a difficult thing to establish in a small sample). To identify those for whom atypical antipsychotics are effective, and in what context, further research on larger series is warranted.
Friedlander and others note that, even with their clinic's conservative prescription practices, one-half the individuals in the sample were taking atypical antipsychotics-even when psychotic symptoms were not documented. We agree with the authors that, in the absence of clearly identified psychiatric disorders for which these medications are indicated, the practice of using either typical or atypical antipsychotics to treat behaviour disturbances is no longer tenable. We urge psychiatrists to identify and carefully monitor, in both their research and clinical practice, the target symptoms that the antipsychotic is intended to address, particularly when the symptoms are not psychotic (as may have been the case for many of the individuals with autism-PDD in the present sample). Proceeding in this way helps to ensure that the old practice of overprescribing neuroleptics, noted by Friedlander and others, does not transfer into overprescribing newer antipsychotic medications, particularly in situations where the prescribing physician does not have access to a comprehensive multidisciplinary evaluation process.
The study by Friedlander and others is an important step toward evaluating the use of atypical antipsychotics in individuals with DDs, but the methodological and other concerns outlined above make it premature to endorse their use. It is our belief, supported by recent consensus guidelines (2) (3) (4) , that a comprehensive evaluation to better understand the underlying cause of the symptoms and behaviour disturbances is essential-in particular, to ascertain whether these are indeed caused by a psychiatric disorder. This approach leads to more effective treatment, more appropriate and targeted use of antipsychotic medication, and fewer side effects. Our mental health support teams provide a full multidisciplinary evaluation, and all patients in our sample had behavioural-psychosocial interventions in addition to psychopharmacological treatment. We intended our paper to illustrate the widespread use of atypical antipsychotic treatment in clinically referred youth with DDs and behavioural problems. How much improvement can be attributed to the atypical antipsychotics is a complex question that indicates the urgent need for more double-blind placebo-controlled trials in youth with DDs.
Our study highlights the need for great caution when using these medications in this population and notes atypical neuroleptic-induced movement disorders not previously well documented. 
Evidence Supports Validity of Seasonal Affective Disorder
Dear Editor:
We were surprised to read in a recent editorial that Dr Paul Grof questions the validity of the diagnosis of seasonal affective disorder (SAD). He writes that "the evidence for the existence of SAD itself is still missing, more than 20 years after it was proposed. In clinical course, genetic, and treatment studies, there is still no convincing justification for the diagnosis of an independent seasonal illness" (1, p 124). This statement seems based more on idiosyncratic opinion than on scientific evidence. First, it is worth clarifying that the DSM-IV classifies SAD as a seasonal pattern specifier for major depressive disorder (MDD) (2), and hence, it is regarded as a subtype of depression rather than an independent diagnostic category. Second, there is ample evidence to demonstrate that seasonal pattern is a valid specifier for MDD and that light therapy is an effective treatment for SAD. Since the condition was first described in 1984, nearly 1000 articles have been indexed on Medline under the heading, "seasonal affective disorder." Indeed, extensive reviews support an argument that there is more evidence for the validity of SAD than for many other well-recognised depressive subtypes, including bipolar II disorder, atypical depression, and postpartum depression (3, 4) . SAD and its treatment have also been comprehensively reviewed and included in Canadian (5), American (6) , and international (7) evidence-based guidelines for the treatment of depressive disorders. We suggest that it is time to leave behind the argument of whether SAD is a valid diagnosis and concentrate instead upon determining the pathophysiology and most effective methods of identifying and treating this prevalent and disabling subtype of depression.
